Succinobucol-eluting Stents Increase Neointimal Thickening and Peri-strut Inflammation in a Porcine Coronary Model

Overview

Journal Catheter Cardiovasc Interv

Specialty Cardiology & Vascular Diseases

Date 2012 May 15

PMID 22581717

Citations 6

Authors

Jonathan Watt

Simon Kennedy

Christopher McCormick

Ejaife O Agbani

Allan McPhaden

Alexander Mullen

Peter Czudaj

Boris Behnisch

Roger M Wadsworth

Keith G Oldroyd

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to assess the efficacy of stent-based delivery of succinobucol alone and in combination with rapamycin in a porcine coronary model.

Background: Current drugs and polymers used to coat coronary stents remain suboptimal in terms of long term efficacy and safety. Succinobucol is a novel derivative of probucol with improved antioxidant and anti-inflammatory properties.

Methods: Polymer-free Yukon stents were coated with 1% succinobucol (SucES), 2% rapamycin (RES), or 1% succinobucol plus 2% rapamycin solutions (SucRES) and compared with a bare metal stent (BMS).

Results: The in vivo release profile of SucES indicated drug release up to 28 days (60% drug released at 7 days); 41 stents (BMS, n = 11; SucES, n =10; RES, n = 10; SucRES, n = 10) were implanted in the coronary arteries of 17 pigs. After 28 days, mean neointimal thickness was 0.31 ± 0.14 mm for BMS, 0.51 ± 0.14 mm for SucES, 0.19 ± 0.11 mm for RES, and 0.36 ± 0.17 mm for SucRES (P < 0.05 for SucES vs. BMS). SucES increased inflammation and fibrin deposition compared with BMS (P < 0.05), whereas RES reduced inflammation compared with BMS (P < 0.05).

Conclusion: In this model, stent-based delivery of 1% succinobucol using a polymer-free stent platform increased neointimal formation and inflammation following coronary stenting.

Citing Articles

Controlled drug delivery from chitosan-coated heparin-loaded nanopores anodically grown on nitinol shape-memory alloy.

Moradi M, Salahinejad E, Sharifi E, Tayebi L Carbohydr Polym. 2023; 314:120961.

PMID: 37173015 PMC: 10585653. DOI: 10.1016/j.carbpol.2023.120961.

Antioxidants in the Fight Against Atherosclerosis: Is This a Dead End?.

Toledo-Ibelles P, Mas-Oliva J Curr Atheroscler Rep. 2018; 20(7):36.

PMID: 29781062 PMC: 5960648. DOI: 10.1007/s11883-018-0737-7.

Polymer-free dual drug-eluting stents evaluated in a porcine model.

Zhang B, Zheng B, Wang X, Shi Q, Jia J, Huo Y BMC Cardiovasc Disord. 2017; 17(1):222.

PMID: 28810900 PMC: 5558731. DOI: 10.1186/s12872-017-0654-7.

Non-polymer drug-eluting coronary stents.

Kommineni N, Saka R, Khan W, Domb A Drug Deliv Transl Res. 2017; 8(4):903-917.

PMID: 28799125 DOI: 10.1007/s13346-017-0414-3.

A minimally invasive endovascular rabbit model for experimental induction of progressive myocardial hypertrophy.

Tsigkas G, Katsanos K, Apostolakis E, Papadimitriou E, Koutsioumpa M, Kagadis G Hypertens Res. 2016; 39(12):840-847.

PMID: 27334064 DOI: 10.1038/hr.2016.66.

References

Deng Y, Wu B, Witting P, Stocker R . Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation. 2004; 110(13):1855-60. DOI: 10.1161/01.CIR.0000142610.10530.25. View

Meng C, Somers P, Rachita C, Holt L, Hoong L, Zheng X . Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett. 2002; 12(18):2545-8. DOI: 10.1016/s0960-894x(02)00516-4. View

Muldrew K, Franks A . Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects. Expert Opin Investig Drugs. 2009; 18(4):531-9. DOI: 10.1517/13543780902849244. View

Wakeyama T, Ogawa H, Iida H, Takaki A, Iwami T, Mochizuki M . Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J. 2003; 67(6):519-24. DOI: 10.1253/circj.67.519. View

Joner M, Finn A, Farb A, Mont E, Kolodgie F, Ladich E . Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48(1):193-202. DOI: 10.1016/j.jacc.2006.03.042. View

Finn A, Nakazawa G, Joner M, Kolodgie F, Mont E, Gold H . Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007; 27(7):1500-10. DOI: 10.1161/ATVBAHA.107.144220. View

Carter A, Aggarwal M, Kopia G, Tio F, Tsao P, Kolata R . Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004; 63(4):617-24. DOI: 10.1016/j.cardiores.2004.04.029. View

Wilson G, Nakazawa G, Schwartz R, Huibregtse B, Poff B, Herbst T . Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009; 120(2):141-9, 1-2. DOI: 10.1161/CIRCULATIONAHA.107.730010. View

Lee H, Jeon B, Won K, Lee C, Park T, Choi W . Gene transfer of redox factor-1 inhibits neointimal formation: involvement of platelet-derived growth factor-beta receptor signaling via the inhibition of the reactive oxygen species-mediated Syk pathway. Circ Res. 2008; 104(2):219-27, 5p following 227. DOI: 10.1161/CIRCRESAHA.108.178699. View

10.

Yokoyama T, Miyauchi K, Kurata T, Sato H, Daida H . Effect of probucol on neointimal thickening in a stent porcine restenosis model. Jpn Heart J. 2004; 45(2):305-13. DOI: 10.1536/jhj.45.305. View

11.

Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S . Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol. 2005; 25(4):748-53. DOI: 10.1161/01.ATV.0000157579.52566.ee. View

12.

Tanaka K, Hayashi K, Shingu T, Kuga Y, Nomura K, Kajiyama G . Probucol inhibits neointimal formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells. Cardiovasc Drugs Ther. 1998; 12(1):19-28. DOI: 10.1023/a:1007777128574. View

13.

Murata S, Sundell C, Lijkwan M, Balsam L, Hammainen P, Coleman C . Effects of AGI-1096, a novel antioxidant compound with anti-inflammatory and antiproliferative properties, on rodent allograft arteriosclerosis. Transplantation. 2004; 77(10):1494-500. DOI: 10.1097/01.tp.0000123076.05313.9f. View

14.

Rosner D, McCarthy N, Bennett M . Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53. Cardiovasc Res. 2005; 66(3):601-10. DOI: 10.1016/j.cardiores.2005.01.006. View

15.

Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T . Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005; 26(15):1475-81. DOI: 10.1093/eurheartj/ehi405. View

16.

Tardif J, McMurray J, Klug E, Small R, Schumi J, Choi J . Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371(9626):1761-8. DOI: 10.1016/S0140-6736(08)60763-1. View

17.

Kanellakis P, Pomilio G, Walker C, Husband A, Huang J, Nestel P . A novel antioxidant 3,7-dihydroxy-isoflav-3-ene (DHIF) inhibits neointimal hyperplasia after vessel injury attenuating reactive oxygen species and nuclear factor-kappaB signaling. Atherosclerosis. 2008; 204(1):66-72. DOI: 10.1016/j.atherosclerosis.2008.09.005. View

18.

Sundell C, Somers P, Meng C, Hoong L, Suen K, Hill R . AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther. 2003; 305(3):1116-23. DOI: 10.1124/jpet.102.048132. View

19.

Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H . Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol. 1998; 82(2):144-7. DOI: 10.1016/s0002-9149(98)00323-3. View

20.

Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B . Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006; 113(2):273-9. DOI: 10.1161/CIRCULATIONAHA.105.575977. View